Internal Medicine News - Rimonabant cuts rate of metabolic syndrome by 53%: selective endocannabinoid type 1 receptor blocker improves weight loss, lipid profile
Sunday, January 4th, 2009MUNICH — The investigational drug rimonabant, first in a new class of agents known as selective endocannabinoid type 1 receptor blockers, is looking more and more like the real deal: a potential blockbuster drug causing sustained weight loss in the obese, reversal of t…
